Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313406578> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W4313406578 endingPage "436" @default.
- W4313406578 startingPage "429" @default.
- W4313406578 abstract "Background/Aim: No practical predictive biomarkers exist to date for the response to androgen receptor-axis targeted (ARAT) therapies in metastatic castration-resistant prostate cancer (mCRPC). This study investigated whether prostate-specific antigen (PSA) kinetics in primary androgen-deprivation therapy for advanced hormone-sensitive prostate cancer may be associated with the response to ARAT agents in mCRPC. Patients and Methods: This study assessed 102 patients with mCRPC treated with enzalutamide or abiraterone to evaluate the associations between clinical outcomes and PSA kinetics, including the ratio of initial to nadir PSA (I/N PSA) level in primary combined androgen blockade. The PSA response was defined as a ≥50% decrease at 3 months from baseline in patients with mCRPC. Results: In patients treated with enzalutamide, the optimal cut-off I/N PSA value for PSA response was 531 ng/ml (sensitivity=66.7%, specificity=88.2%, area under the curve=0.73, using a receiver operating characteristic curve). The PSA response was 83.3% and 25.0% in the high and low I/N PSA groups, respectively. The median overall survival and radiographic progression-free survival from enzalutamide initiation were longer for the high compared to the low I/N PSA group. Multivariate analysis revealed I/N PSA (hazard ratio=0.275, p=0.026) as an independent risk factor for overall survival in the patients treated with enzalutamide. In contrast, I/N PSA showed no predictive ability for PSA response in patients treated with abiraterone. Conclusion: In patients with mCRPC, I/N PSA can be a practical predictive biomarker for response to the ARAT agent enzalutamide." @default.
- W4313406578 created "2023-01-06" @default.
- W4313406578 creator A5010953950 @default.
- W4313406578 creator A5020076297 @default.
- W4313406578 creator A5081326354 @default.
- W4313406578 creator A5091118998 @default.
- W4313406578 date "2022-12-30" @default.
- W4313406578 modified "2023-10-18" @default.
- W4313406578 title "Prostate-specific Antigen Kinetics During Androgen-deprivation Therapy Predict Response to Enzalutamide in Metastatic Castration-resistant Prostate Cancer" @default.
- W4313406578 doi "https://doi.org/10.21873/anticanres.16178" @default.
- W4313406578 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36585210" @default.
- W4313406578 hasPublicationYear "2022" @default.
- W4313406578 type Work @default.
- W4313406578 citedByCount "0" @default.
- W4313406578 crossrefType "journal-article" @default.
- W4313406578 hasAuthorship W4313406578A5010953950 @default.
- W4313406578 hasAuthorship W4313406578A5020076297 @default.
- W4313406578 hasAuthorship W4313406578A5081326354 @default.
- W4313406578 hasAuthorship W4313406578A5091118998 @default.
- W4313406578 hasBestOaLocation W43134065781 @default.
- W4313406578 hasConcept C121608353 @default.
- W4313406578 hasConcept C126322002 @default.
- W4313406578 hasConcept C126894567 @default.
- W4313406578 hasConcept C143998085 @default.
- W4313406578 hasConcept C170493617 @default.
- W4313406578 hasConcept C207103383 @default.
- W4313406578 hasConcept C2776551883 @default.
- W4313406578 hasConcept C2777899217 @default.
- W4313406578 hasConcept C2777911890 @default.
- W4313406578 hasConcept C2778468042 @default.
- W4313406578 hasConcept C2780192828 @default.
- W4313406578 hasConcept C2781406297 @default.
- W4313406578 hasConcept C44249647 @default.
- W4313406578 hasConcept C58471807 @default.
- W4313406578 hasConcept C61367390 @default.
- W4313406578 hasConcept C71315377 @default.
- W4313406578 hasConcept C71924100 @default.
- W4313406578 hasConceptScore W4313406578C121608353 @default.
- W4313406578 hasConceptScore W4313406578C126322002 @default.
- W4313406578 hasConceptScore W4313406578C126894567 @default.
- W4313406578 hasConceptScore W4313406578C143998085 @default.
- W4313406578 hasConceptScore W4313406578C170493617 @default.
- W4313406578 hasConceptScore W4313406578C207103383 @default.
- W4313406578 hasConceptScore W4313406578C2776551883 @default.
- W4313406578 hasConceptScore W4313406578C2777899217 @default.
- W4313406578 hasConceptScore W4313406578C2777911890 @default.
- W4313406578 hasConceptScore W4313406578C2778468042 @default.
- W4313406578 hasConceptScore W4313406578C2780192828 @default.
- W4313406578 hasConceptScore W4313406578C2781406297 @default.
- W4313406578 hasConceptScore W4313406578C44249647 @default.
- W4313406578 hasConceptScore W4313406578C58471807 @default.
- W4313406578 hasConceptScore W4313406578C61367390 @default.
- W4313406578 hasConceptScore W4313406578C71315377 @default.
- W4313406578 hasConceptScore W4313406578C71924100 @default.
- W4313406578 hasIssue "1" @default.
- W4313406578 hasLocation W43134065781 @default.
- W4313406578 hasLocation W43134065782 @default.
- W4313406578 hasOpenAccess W4313406578 @default.
- W4313406578 hasPrimaryLocation W43134065781 @default.
- W4313406578 hasRelatedWork W2344231551 @default.
- W4313406578 hasRelatedWork W2435930479 @default.
- W4313406578 hasRelatedWork W2469134207 @default.
- W4313406578 hasRelatedWork W2595758682 @default.
- W4313406578 hasRelatedWork W2768081255 @default.
- W4313406578 hasRelatedWork W2941511463 @default.
- W4313406578 hasRelatedWork W3030000199 @default.
- W4313406578 hasRelatedWork W4287355568 @default.
- W4313406578 hasRelatedWork W794048265 @default.
- W4313406578 hasRelatedWork W4206870430 @default.
- W4313406578 hasVolume "43" @default.
- W4313406578 isParatext "false" @default.
- W4313406578 isRetracted "false" @default.
- W4313406578 workType "article" @default.